Align Technology, Inc. (NASDAQ:ALGN) Stock Has Average Price Target of $193.08 According to Analysts

Shares of Align Technology, Inc. (NASDAQ:ALGN) have received a consensus rating of “Moderate Buy” from the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $193.08.

A number of equities research analysts have recently commented on ALGN shares. BMO Capital Markets started coverage on Align Technology in a research note on Wednesday, July 8th. They set an “outperform” rating and a $209.00 target price on the stock. Needham & Company LLC restated a “hold” rating on shares of Align Technology in a research report on Thursday. Evercore downgraded shares of Align Technology from an “outperform” rating to an “in-line” rating and set a $155.00 price objective for the company. in a report on Monday, October 5th. Wall Street Zen lowered shares of Align Technology from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. Finally, Zacks Research lowered shares of Align Technology from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 15th.

Align Technology News Roundup

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Align reported third-quarter adjusted earnings of $2.80 per share and revenue of approximately $1.01 billion, exceeding analyst estimates. Higher clear-aligner shipments and an improvement in North American orthodontist shipments provided support. Align Technology beats Q3 earnings and revenue estimates
• Positive Sentiment: The company’s competitive position appears to be improving, while increased iTero scanner installations could support longer-term digital-dentistry adoption. Align Technology competitive threat eased
• Neutral Sentiment: Align guided to fourth-quarter 2026 revenue of $1.0 billion, essentially matching consensus expectations. The in-line outlook offers limited upside surprise for the stock. Align Technology provides fourth-quarter guidance
• Negative Sentiment: Management lowered its 2026 sales outlook despite the quarterly beat, reinforcing concerns that demand and revenue growth remain sluggish. Analysts also flagged lower scanner revenue, even as iTero installations increased. ALGN Q3 earnings and lowered 2026 sales view
• Negative Sentiment: Jefferies cut its price target to $170 from $185, while Morgan Stanley reduced its target to $175 from $188. The reductions indicate more cautious expectations for growth and valuation. Jefferies reduces Align Technology price target
• Negative Sentiment: A CEO succession and management transition add an element of execution uncertainty while the company works to restore growth. Align Technology CEO succession plan

Align Technology Stock Down 2.5%

NASDAQ ALGN opened at $149.89 on Friday. The company has a market cap of $10.73 billion, a price-to-earnings ratio of 21.82, a P/E/G ratio of 1.65 and a beta of 1.67. Align Technology has a 52 week low of $130.23 and a 52 week high of $200.43. The business has a 50 day moving average price of $150.45 and a 200-day moving average price of $168.76.

Align Technology (NASDAQ:ALGN) last issued its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.03. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1 billion. Align Technology had a net margin of 11.83% and a return on equity of 15.96%. The business’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the company earned $2.61 earnings per share. On average, equities research analysts anticipate that Align Technology will post 9.27 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Covestor Ltd grew its holdings in Align Technology by 43.9% during the 3rd quarter. Covestor Ltd now owns 423 shares of the medical equipment provider’s stock valued at $62,000 after buying an additional 129 shares in the last quarter. GRIMES & Co WEALTH MANAGEMENT LLC boosted its holdings in shares of Align Technology by 10.5% during the 3rd quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 36,696 shares of the medical equipment provider’s stock valued at $5,334,000 after purchasing an additional 3,488 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Align Technology during the third quarter valued at about $2,482,000. ProShare Advisors LLC grew its position in shares of Align Technology by 1.9% during the third quarter. ProShare Advisors LLC now owns 10,943 shares of the medical equipment provider’s stock valued at $1,591,000 after purchasing an additional 203 shares in the last quarter. Finally, Vise Technologies Inc. purchased a new position in shares of Align Technology during the third quarter valued at about $339,000. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

About Align Technology

Align Technology, Inc is a global medical device company focused on digital orthodontics and restorative dentistry. Founded in 1997, the company is best known for the Invisalign system, a series of clear, removable aligners designed to gradually move teeth and treat a range of orthodontic conditions.

Align’s products and services also include digital scanning and dental practice solutions. Its iTero intraoral scanners create digital impressions for orthodontic and restorative procedures, while its exocad business develops computer-aided design and computer-aided manufacturing software used by dental laboratories, clinicians and other dental professionals.

The company serves orthodontists, dentists, dental laboratories and patients in numerous markets worldwide.